Evidence map›Paper›PMID 27013100›Full record

ArticleJournal of lipid research2016

ATRA transcriptionally induces nSMase2 through CBP/p300-mediated histone acetylation.

Christopher J Clarke, Achraf A Shamseddine, Joseph J Jacob, Gabrielle Khalife, Tara A Burns, Yusuf A Hannun

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Retinoic acid in health and disease.Signal transduction and targeted therapy · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Epigenetics and Sphingolipid Metabolism in Health and Disease.International journal of biopharmaceutical sciences · 2018
    Article
  8. Sphingolipids and their metabolism in physiology and disease.Nature reviews. Molecular cell biology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Christopher J ClarkeDepartment of Medicine and Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY.
Achraf A ShamseddineDepartment of Medicine and Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY.
Joseph J JacobDepartment of Medicine and Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY.
Gabrielle KhalifeDepartment of Medicine and Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY.
Tara A BurnsDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC.
Yusuf A HannunDepartment of Medicine and Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY yusuf.hannun@stonybrookmedicine.edu.
Stony Brook University · USMedical University of South Carolina · US

Funding

Sphingolipids in Cancer Therapy and AngiogenesisP01CA097132 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI YUSUF AWNI HANNUN · 2003 to 2026
$30.8M
Neutral Sphingomyelinases and Bioactive CeramidesR35GM118128 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI HANNUN, YUSUF AWNI · 2016 to 2025
$7.9M
NCI NIH HHS P01 CA097132NIGMS NIH HHS R35 GM118128
6 · The paper itself

Abstract

Neutral sphingomyelinase-2 (nSMase2) is a key ceramide-producing enzyme in cellular stress responses. While many posttranslational regulators of nSMase2 are known, emerging evidence suggests a more protracted regulation of nSMase2 at the transcriptional level. Previously, we reported that nSMase2 is induced by all-trans retinoic acid (ATRA) in MCF7 cells and implicated nSMase2 in ATRA-induced growth arrest. Here, we further investigated how ATRA regulates nSMase2. We find that ATRA regulates nSMase2 transcriptionally through the retinoic acid receptor-α, but this is independent of previously identified transcriptional regulators of nSMase2 (Sp1, Sp3, Runx2) and is not through increased promoter activity. Epigenetically, the nSMase2 gene is not repressively methylated in MCF7 cells. However, inhibition of histone deacetylases (HDACs) with trichostatin A (TSA) induced nSMase2 comparably to ATRA; furthermore, combined ATRA and TSA treatment was not additive, suggesting ATRA regulates nSMase2 through direct modulation of histone acetylation. Confirming this, the histone acetyltransferases CREB-binding protein and p300 were required for ATRA induction of nSMase2. Finally, use of class-specific HDAC inhibitors suggested that HDAC4 and/or HDAC5 are negative regulators of nSMase2 expression. Collectively, these results identify a novel pathway of nSMase2 regulation and suggest that physiological or pharmacological modulation of histone acetylation can directly affect nSMase2 levels.

Indexed as

AcetylationDNA MethylationEnzyme InductionGene Expression Regulation, NeoplasticHistone DeacetylasesHistonesHumansHydroxamic AcidsMCF-7 CellsNuclear Receptor Subfamily 1, Group F, Member 1p300-CBP Transcription FactorsPromoter Regions, GeneticProtein Processing, Post-TranslationalSphingomyelin PhosphodiesteraseTranscriptional ActivationTranscription, GeneticHistone DeacetylasesHistonesHydroxamic AcidsNuclear Receptor Subfamily 1, Group F, Member 1p300-CBP Transcription FactorsRORA protein, humanSMPD3 protein, humanSphingomyelin PhosphodiesteraseTretinointrichostatin Aall-trans retinoic acidepigenetichistone acetyltransferasehistone deacetylaseneutral sphingomyelinase-2nuclear receptorsretinoidssignal transductionsphingolipidstranscription

Identifiers

PMID27013100
PMCPMC4847633
OpenAlexW2310278026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.